New Amsterdam Pharma
Juliette Audet is Partner in the Naarden office and joined the Forbion team in 2019. She currently serves as a board member for NewAmsterdam Pharma. Prior to joining Forbion, Juliette was a Principal at Novartis Venture Fund based in Cambridge (USA). There she sat on the boards of TScan Therapeutics and Annexon Biosciences as an observer. Juliette was also leading the management of NVF’s public equities. Before that, Juliette was a Senior Manager of Strategy at Novartis AG, where she worked with the senior executive team of the Pharma division. Juliette spent the first 4 years of her career in management consulting at McKinsey and Company focusing on Pharma and Biotech, based out of the Swiss and then New York offices. Juliette graduated with distinction from Harvard Business School in 2015 (MBA) and received her MSc in Physics (Suma Cum Laude) from EPFL (Lausanne, Swiss Federal Institute of Technology) in 2010.
This person is not in the org chart
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.